Sorafenib is a multiple receptor tyrosine kinase inhibitor known to prolong overall survival in patients with advanced hepatocellular carcinoma (HCC). Predicting this drug’s survival benefits is challenging because clinical responses are rarely measurable during treatment. | Serum cytokine profiles predict survival benefits in patients with advanced hepatocellular carcinoma treated with sorafenib A retrospective cohort study